AR023299A1 - UNA FORMULACION DE LIBERACION PROLONGADA DE UN COMPUESTO MACRoLIDO - Google Patents
UNA FORMULACION DE LIBERACION PROLONGADA DE UN COMPUESTO MACRoLIDOInfo
- Publication number
- AR023299A1 AR023299A1 ARP990101353A ARP990101353A AR023299A1 AR 023299 A1 AR023299 A1 AR 023299A1 AR P990101353 A ARP990101353 A AR P990101353A AR P990101353 A ARP990101353 A AR P990101353A AR 023299 A1 AR023299 A1 AR 023299A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation
- compound
- prolonged release
- macrolid
- macrolide compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyrane Compounds (AREA)
Abstract
Se proporciona una formulacion oral de un compuesto macrolido donde la disolucion de éste se realiza bajo liberacion prolongada; y una formulacion deliberacion prolongada que contiene una composicion en solucion solida, donde el compuesto macrolido está presente en un estado amorfo en una base solida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7903998 | 1998-03-26 | ||
JP18296398 | 1998-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR023299A1 true AR023299A1 (es) | 2002-09-04 |
Family
ID=26420115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990101353A AR023299A1 (es) | 1998-03-26 | 1999-03-26 | UNA FORMULACION DE LIBERACION PROLONGADA DE UN COMPUESTO MACRoLIDO |
Country Status (32)
Country | Link |
---|---|
US (5) | US6440458B1 (es) |
EP (3) | EP2198858B1 (es) |
JP (4) | JP3714970B2 (es) |
KR (3) | KR100505464B1 (es) |
CN (1) | CN1229111C (es) |
AR (1) | AR023299A1 (es) |
AT (3) | ATE269075T1 (es) |
AU (1) | AU749623B2 (es) |
BR (1) | BRPI9909201B8 (es) |
CA (1) | CA2322516C (es) |
CZ (1) | CZ300548B6 (es) |
DE (2) | DE69918074T2 (es) |
DK (3) | DK1064942T3 (es) |
ES (3) | ES2219000T3 (es) |
HK (1) | HK1038185A1 (es) |
HR (1) | HRP20000707B1 (es) |
HU (1) | HU230889B1 (es) |
ID (1) | ID27825A (es) |
IL (1) | IL138466A (es) |
ME (2) | MEP30008A (es) |
NO (1) | NO330578B1 (es) |
NZ (1) | NZ507211A (es) |
PL (1) | PL193244B1 (es) |
PT (3) | PT2198858E (es) |
RS (1) | RS50164B (es) |
RU (1) | RU2214244C9 (es) |
SI (1) | SI1064942T1 (es) |
SK (1) | SK286887B6 (es) |
TR (1) | TR200002771T2 (es) |
TW (2) | TWI235068B (es) |
WO (1) | WO1999049863A1 (es) |
ZA (1) | ZA200004963B (es) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7399480B2 (en) * | 1997-09-26 | 2008-07-15 | Abbott Laboratories | Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices |
US20030129215A1 (en) * | 1998-09-24 | 2003-07-10 | T-Ram, Inc. | Medical devices containing rapamycin analogs |
US6890546B2 (en) * | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
PT2198858E (pt) * | 1998-03-26 | 2011-09-01 | Astellas Pharma Inc | Composição farmacêutica de libertação constante que contém um macrólido como o tacrolimus |
US7455853B2 (en) * | 1998-09-24 | 2008-11-25 | Abbott Cardiovascular Systems Inc. | Medical devices containing rapamycin analogs |
US6855172B2 (en) | 1998-10-13 | 2005-02-15 | Dry, Inc. | Dry-cleaning article, composition and methods |
US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US7807211B2 (en) | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
KR20020083171A (ko) * | 2000-03-08 | 2002-11-01 | 아베데 파르마 게엠베하 운트 콤파니 카게 | 활성 성분의 방출 조절을 위한 삭카로스 지방산에스테르를 함유하는 약제학적 제제 |
EP2266549B1 (en) | 2000-06-27 | 2019-08-07 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
DK1296651T3 (da) * | 2000-06-27 | 2008-02-11 | Vectura Ltd | Fremgangsmåde til fremstilling af partikler til anvendelse i et farmaceutisk præparat |
US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
NZ527692A (en) | 2001-02-19 | 2005-05-27 | Novartis Ag | Cancer treatment |
US6645946B1 (en) | 2001-03-27 | 2003-11-11 | Pro-Pharmaceuticals, Inc. | Delivery of a therapeutic agent in a formulation for reduced toxicity |
DK1383516T3 (da) | 2001-03-27 | 2012-02-20 | Pro Pharmaceuticals Inc | Indgivelse af et polysaccharid samtidig med et kemoterapeutisk middel til behandling af cancer |
GB0108498D0 (en) * | 2001-04-04 | 2001-05-23 | Novartis Ag | Organic Compounds |
WO2002089796A2 (en) * | 2001-05-09 | 2002-11-14 | Novartis Ag | Methods for selective immunomodulation using pimecrolimus |
AUPR529701A0 (en) * | 2001-05-28 | 2001-06-21 | Fujisawa Pharmaceutical Co., Ltd. | Pharmaceutical composition |
US20080145402A1 (en) * | 2001-09-10 | 2008-06-19 | Abbott Cardiovascular Systems Inc. | Medical Devices Containing Rapamycin Analogs |
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
EP1443910A1 (en) | 2001-11-02 | 2004-08-11 | Wockhardt Limited | Controlled release compositions for macrolide antimicrobial agents |
JP2003327536A (ja) * | 2002-03-07 | 2003-11-19 | Kitasato Inst:The | ヒト免疫不全症候群ウイルスの感染、増殖抑制剤 |
US20060171984A1 (en) * | 2002-09-06 | 2006-08-03 | Cromack Keith R | Device having hydration inhibitor |
ES2552682T3 (es) | 2003-03-10 | 2015-12-01 | Merck Sharp & Dohme Corp. | Agentes antibacterianos novedosos |
US20040185009A1 (en) * | 2003-03-19 | 2004-09-23 | Dexcel Pharma Technologies Ltd. | Composition and device for treating periodontal diseases |
GB0307866D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
GB0307867D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
EP2529730A1 (en) * | 2003-06-16 | 2012-12-05 | ANDRX Pharmaceuticals LLC. | Oral sustained-release composition |
US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
US20060177500A1 (en) * | 2003-07-09 | 2006-08-10 | Hee-Jong Shin | Solid dispersion of tacrolimus |
WO2005007110A2 (en) * | 2003-07-11 | 2005-01-27 | Pro-Pharmaceuticals, Inc. | Compositions and methods for hydrophobic drug delivery |
DK1663217T3 (da) * | 2003-08-29 | 2010-11-08 | Lifecycle Pharma As | Faste dispersioner indeholdende tacrolimus |
PL1663217T3 (pl) | 2003-08-29 | 2010-12-31 | Lifecycle Pharma As | Stałe dyspersje zawierające takrolimus |
US20050053664A1 (en) * | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
EP1675576A1 (en) * | 2003-10-03 | 2006-07-05 | LifeCycle Pharma A/S | A method for preparing modified release pharmaceutical compositions |
US7285544B2 (en) * | 2003-11-18 | 2007-10-23 | Bernstein Eric F | Use of nitroxides in treating skin disease |
KR100485877B1 (ko) * | 2003-12-30 | 2005-04-28 | 종근당바이오 주식회사 | 타크롤리무스를 생산하는 미생물 및 이를 이용한타크롤리무스의 대량 생산방법 |
WO2005063242A1 (en) * | 2003-12-30 | 2005-07-14 | Astellas Pharma Inc. | Use of macrolides for treating or preventing airflow obstruction |
WO2005079314A2 (en) * | 2004-02-13 | 2005-09-01 | Pro-Pharmaceuticals, Inc. | Compositions and methods used to treat acne and candida |
EP1773128A2 (en) * | 2004-08-02 | 2007-04-18 | Pro-Pharmaceuticals, Inc. | Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins |
WO2006021443A2 (en) * | 2004-08-26 | 2006-03-02 | Novartis Ag | Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator |
BRPI0516170A (pt) * | 2004-09-29 | 2008-08-26 | Cordis Corp | formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina |
WO2006060617A1 (en) * | 2004-12-01 | 2006-06-08 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Ascomycin crystalline forms and preparation thereof |
JP2007527434A (ja) * | 2005-01-05 | 2007-09-27 | テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ | 非晶質タクロリマス及びその調製 |
KR100678824B1 (ko) * | 2005-02-04 | 2007-02-05 | 한미약품 주식회사 | 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물 |
KR20070121758A (ko) * | 2005-03-17 | 2007-12-27 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 면역 억제 화합물의 주사가능한 조성물 |
DE602007002905D1 (de) * | 2006-01-23 | 2009-12-03 | Yissum Res Dev Co | Mikrokügelchen mit nanokapseln, die ein lipophiles arzneimittel enthalten |
HUP0600097A3 (en) * | 2006-02-08 | 2008-07-28 | Richter Gedeon Nyrt | Pharmaceutical compositions comprising tacrolimus and process for their preparation |
JP2007308479A (ja) | 2006-04-20 | 2007-11-29 | Shin Etsu Chem Co Ltd | 固体分散体製剤 |
EP2067475A4 (en) * | 2006-09-26 | 2010-12-15 | Astellas Pharma Inc | PREPARATION FOR TACROLIMUS MAINTAINED RELEASE |
EP1938804A1 (en) * | 2006-12-22 | 2008-07-02 | Novartis AG | Pharmaceutical formulation comprising neurokinin antagonist |
US20080221047A1 (en) * | 2006-12-27 | 2008-09-11 | Astellas Pharma Inc., | Aminoakyl methacrylate copolymer E for maintaining solubility of poorly-soluble drug |
CN101573109A (zh) * | 2006-12-28 | 2009-11-04 | 利默里克生物制药公司 | 用于治疗的方法和组合物 |
WO2008084698A1 (ja) | 2006-12-28 | 2008-07-17 | Astellas Pharma Inc. | タクロリムス徐放性医薬組成物 |
US7521523B2 (en) | 2006-12-28 | 2009-04-21 | Eastman Chemical Company | Oxygen-scavenging polyester compositions useful in packaging |
WO2008127746A1 (en) | 2007-01-10 | 2008-10-23 | Board Of Regents The University Of Texas System | Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery |
KR20100014629A (ko) | 2007-03-29 | 2010-02-10 | 파나세아 바이오테크 리미티드 | 타크로리무스의 변형제형 |
ITMI20070720A1 (it) * | 2007-04-06 | 2008-10-07 | Monteresearch Srl | Composizioni orali contenenti tacrolimus in forma amorfa |
WO2008135828A2 (en) | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
WO2008135855A2 (en) | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer |
ES2634153T3 (es) | 2007-05-30 | 2017-09-26 | Veloxis Pharmaceuticals A/S | Forma de dosificación oral de una vez al día que comprende tacrolimus |
US8974827B2 (en) | 2007-06-04 | 2015-03-10 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
WO2008149230A2 (en) | 2007-06-04 | 2008-12-11 | Pfizer Products Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate |
CA2693338A1 (en) * | 2007-07-31 | 2009-02-05 | Limerick Biopharma, Inc. | Phosphorylated pyrone analogs and methods |
AU2008303129B2 (en) | 2007-09-25 | 2013-08-01 | Formulex Pharma Innovations Ltd. | Compositions comprising lipophilic active compounds and method for their preparation |
CN105732745A (zh) | 2007-10-25 | 2016-07-06 | 森普拉制药公司 | 大环内酯类抗菌剂的制备方法 |
TW200932240A (en) | 2007-10-25 | 2009-08-01 | Astellas Pharma Inc | Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production |
KR20090044269A (ko) * | 2007-10-31 | 2009-05-07 | (주)아모레퍼시픽 | 서방성 나노입자 및 이를 함유하는 화장료 조성물 |
EP2240162A4 (en) | 2007-12-06 | 2013-10-09 | Bend Res Inc | NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER |
WO2009073215A1 (en) | 2007-12-06 | 2009-06-11 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
CL2008000374A1 (es) * | 2008-02-05 | 2008-04-04 | Igloo Zone Chile S A | Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve |
US8222272B2 (en) * | 2008-04-11 | 2012-07-17 | Roxane Laboratories, Inc. | Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus) |
EP2313419A1 (en) * | 2008-06-17 | 2011-04-27 | Biotica Technology Limited | Novel compounds and methods for their production |
ES2565083T3 (es) | 2008-10-24 | 2016-03-31 | Cempra Pharmaceuticals, Inc. | Biodefensas usando macrólidos que contienen triazol |
EP3045043B1 (en) | 2009-02-26 | 2020-04-29 | Relmada Therapeutics, Inc. | Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use |
US9937194B1 (en) | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
CN102724874B (zh) | 2009-09-10 | 2018-06-01 | 森普拉制药公司 | 治疗疟疾、结核病和mac疾病的方法 |
DK2575769T3 (en) | 2010-02-17 | 2016-09-26 | Veloxis Pharmaceuticals As | stabilized tacrolismussammensætning |
CN102414951A (zh) | 2010-02-25 | 2012-04-11 | 松下电器产业株式会社 | 供需控制装置、供需控制方法及程序 |
CN103052382B (zh) | 2010-07-14 | 2014-10-22 | 千寿制药株式会社 | α-酮酰胺衍生物的固体分散体 |
WO2012026896A1 (en) * | 2010-08-25 | 2012-03-01 | Les Laboratoires Medis Sa | Surface modified micronized tacrolimus crystalline particles and pharmaceutical compositions thereof |
EP2613630A4 (en) | 2010-09-10 | 2014-01-15 | Cempra Pharmaceuticals Inc | FLUOROCETOLIDES FORMING HYDROGEN LINKS TO TREAT DISEASES |
WO2013025449A1 (en) * | 2011-08-16 | 2013-02-21 | Merck Sharp & Dohme Corp. | Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions |
US20140242162A1 (en) * | 2011-10-06 | 2014-08-28 | Novartis Ag | Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin |
KR20140139083A (ko) | 2012-03-27 | 2014-12-04 | 셈프라 파마슈티컬스, 인크. | 마크롤라이드계 항생제를 투여하기 위한 비경구 제제 |
ES2624229T3 (es) * | 2012-07-06 | 2017-07-13 | Godo Shusei Co., Ltd. | Método para separar un compuesto macrólido ciclico |
JP6426696B2 (ja) | 2013-03-14 | 2018-11-21 | センプラ ファーマシューティカルズ,インコーポレイテッド | 呼吸器疾患の治療のための方法および製剤 |
WO2014145210A1 (en) | 2013-03-15 | 2014-09-18 | Cempra Pharmaceuticals, Inc. | Convergent processes for preparing macrolide antibacterial agents |
US9168246B2 (en) | 2013-06-27 | 2015-10-27 | Veloxis Pharmaceutical A/S | Regimen for suppressing organ rejection |
CN103432099A (zh) * | 2013-08-13 | 2013-12-11 | 江苏正大清江制药有限公司 | 一种他克莫司缓释胶囊及其制备方法 |
US20170072058A1 (en) | 2014-11-21 | 2017-03-16 | Solipharma Llc | Pharmaceutical composition containing tacrolimus and preparation methods thereof |
CN104473907A (zh) * | 2014-12-25 | 2015-04-01 | 北京华禧联合科技发展有限公司 | 一种他克莫司的口服缓释制剂 |
WO2016185443A1 (en) | 2015-05-20 | 2016-11-24 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
CN104840446B (zh) * | 2015-05-27 | 2017-08-11 | 福建科瑞药业有限公司 | 一种他克莫司药物组合物及其制备方法 |
WO2017180842A1 (en) | 2016-04-15 | 2017-10-19 | Bioatla, Llc | Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof |
WO2018049174A1 (en) * | 2016-09-08 | 2018-03-15 | Synergistic Therapeutics, Llc | Topical hair growth formulation |
AU2017363970A1 (en) | 2016-11-23 | 2019-06-20 | Novartis Ag | Methods of enhancing immune response with everolimus, dactolisib or both |
WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
KR102081176B1 (ko) * | 2018-06-22 | 2020-02-25 | 주식회사 종근당 | 타크로리무스를 포함하는 서방형 약제학적 제제 |
JP2022515069A (ja) * | 2018-12-18 | 2022-02-17 | ニュートリション アンド バイオサイエンシズ ユーエスエー 1,リミティド ライアビリティ カンパニー | エチルセルロースを含む徐放性組成物 |
GR1009790B (el) | 2019-03-20 | 2020-08-03 | Φαρματεν Α.Β.Ε.Ε. | Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει τακρολιμους |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL32929A (en) | 1968-09-03 | 1973-08-29 | Banker G | Controlled-release pharmaceutical compositions containing a polymer for chemisorbing the active drug |
US4127647A (en) | 1975-04-08 | 1978-11-28 | Meiji Seika Kaisha, Ltd. | Process for preparation of stable amorphous macrolide antibiotic solids |
US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4894366A (en) | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
JPS62208103A (ja) | 1986-03-07 | 1987-09-12 | Yokogawa Hewlett Packard Ltd | ロボツト運動制御システム |
GB8608080D0 (en) * | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
JPS63150220A (ja) * | 1986-12-15 | 1988-06-22 | Dainippon Pharmaceut Co Ltd | 経口用固形製剤の製造方法 |
US4968508A (en) | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
JP2822389B2 (ja) | 1987-06-05 | 1998-11-11 | 藤沢薬品工業株式会社 | 抗fr−900506物質抗体、および高感度酵素免疫測定法 |
EP0346427B1 (en) | 1987-12-09 | 1995-03-29 | FISONS plc | Macrocyclic compounds |
DE3742525C2 (de) | 1987-12-11 | 1998-02-19 | Hertz Inst Heinrich | Verfahren zur Herstellung von Metallalkylverbindungen und deren Verwendung |
FR2624732B1 (fr) | 1987-12-21 | 1991-02-15 | Synthelabo | Formulation pharmaceutique a liberation prolongee |
JPH02232814A (ja) | 1989-03-07 | 1990-09-14 | Fuji Photo Film Co Ltd | 磁気記録媒体 |
IE66485B1 (en) * | 1989-07-05 | 1996-01-10 | Fujisawa Pharmaceutical Co | Aqueous liquid composition for external use |
KR0159766B1 (ko) | 1989-10-16 | 1998-12-01 | 후지사와 토모키치로 | 양모제 조성물 |
DE10299040I2 (de) | 1989-11-09 | 2006-08-24 | Novartis Ag | Heteroatome enthaltende tricyclische Verbindungen |
JPH03232814A (ja) | 1990-02-08 | 1991-10-16 | Shin Etsu Chem Co Ltd | 徐放性錠剤の製造方法 |
JPH05505798A (ja) | 1990-03-13 | 1993-08-26 | フアイソンズ・ピーエルシー | 免疫抑制マクロ環状化合物 |
WO1991019495A1 (en) | 1990-06-11 | 1991-12-26 | Fujisawa Pharmaceutical Co., Ltd. | Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease |
US5643901A (en) | 1990-06-11 | 1997-07-01 | Fujisawa Pharmaceutical Co., Ltd. | Medicament for treating idiopathic thrombocytopenic purpura |
MY110418A (en) | 1990-07-02 | 1998-05-30 | Novartis Ag | Heteroatoms-containing tricyclic compounds. |
EP0480623A1 (en) | 1990-10-11 | 1992-04-15 | Merck & Co. Inc. | New halomacrolides and derivatives having immunosuppressive activity |
US5247076A (en) | 1991-09-09 | 1993-09-21 | Merck & Co., Inc. | Imidazolidyl macrolides having immunosuppressive activity |
US5208241A (en) | 1991-09-09 | 1993-05-04 | Merck & Co., Inc. | N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity |
US5252732A (en) | 1991-09-09 | 1993-10-12 | Merck & Co., Inc. | D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity |
JP3128320B2 (ja) | 1992-03-28 | 2001-01-29 | 株式会社常盤電機 | 不燃性シート及びその製造方法 |
GB9208492D0 (en) * | 1992-04-16 | 1992-06-03 | Glaxo Spa | Heterocyclic compounds |
GB9209882D0 (en) * | 1992-05-07 | 1992-06-24 | Glaxo Lab Sa | Compositions |
HUT66531A (en) | 1992-05-07 | 1994-12-28 | Sandoz Ag | Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them |
JP2707023B2 (ja) * | 1992-07-01 | 1998-01-28 | 株式会社大塚製薬工場 | 経口吸収用製剤 |
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
AU686115B2 (en) | 1992-11-02 | 1998-02-05 | Fujisawa Pharmaceutical Co., Ltd. | Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation |
ES2134860T3 (es) * | 1992-11-18 | 1999-10-16 | Fujisawa Pharmaceutical Co | Preparacion farmaceutica de accion prolongada. |
MY110603A (en) | 1993-05-27 | 1998-08-29 | Novartis Ag | Tetrahydropyran derivatives |
US6204243B1 (en) | 1993-09-01 | 2001-03-20 | Novatis Ag | Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis |
DE4329503A1 (de) | 1993-09-01 | 1995-03-02 | Galenik Labor Freiburg Gmbh | Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa |
JP3232814B2 (ja) | 1993-09-22 | 2001-11-26 | ジェイエスアール株式会社 | 感熱記録媒体用インキ組成物 |
ES2163504T5 (es) * | 1994-05-06 | 2008-05-16 | Pfizer Inc. | Formas de dosificacion de liberacion controlada de azitromicina. |
AR004480A1 (es) | 1995-04-06 | 1998-12-16 | Amico Derin C D | Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen |
FR2736550B1 (fr) * | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
JPH11512096A (ja) * | 1995-08-24 | 1999-10-19 | メルク エンド カンパニー インコーポレーテッド | イミダゾリルマクロライド免疫抑制剤の製造方法 |
US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
ZA9710927B (en) | 1996-12-06 | 1998-06-15 | Fujisawa Pharmaceutical Co | Pharmaceutical composition. |
PT2198858E (pt) * | 1998-03-26 | 2011-09-01 | Astellas Pharma Inc | Composição farmacêutica de libertação constante que contém um macrólido como o tacrolimus |
-
1999
- 1999-03-25 PT PT10152774T patent/PT2198858E/pt unknown
- 1999-03-25 RS YUP-580/00A patent/RS50164B/sr unknown
- 1999-03-25 CN CNB998064157A patent/CN1229111C/zh not_active Expired - Lifetime
- 1999-03-25 SI SI9930622T patent/SI1064942T1/xx unknown
- 1999-03-25 DK DK99909332T patent/DK1064942T3/da active
- 1999-03-25 PL PL343096A patent/PL193244B1/pl unknown
- 1999-03-25 ES ES99909332T patent/ES2219000T3/es not_active Expired - Lifetime
- 1999-03-25 EP EP10152774A patent/EP2198858B1/en not_active Expired - Lifetime
- 1999-03-25 ME MEP-300/08A patent/MEP30008A/xx unknown
- 1999-03-25 ID IDW20002175A patent/ID27825A/id unknown
- 1999-03-25 ME MEP-2008-300A patent/ME00189B/me unknown
- 1999-03-25 PT PT04002277T patent/PT1421939E/pt unknown
- 1999-03-25 KR KR10-2003-7005713A patent/KR100505464B1/ko not_active IP Right Cessation
- 1999-03-25 PT PT99909332T patent/PT1064942E/pt unknown
- 1999-03-25 ES ES10152774T patent/ES2367294T3/es not_active Expired - Lifetime
- 1999-03-25 WO PCT/JP1999/001499 patent/WO1999049863A1/ja active IP Right Grant
- 1999-03-25 NZ NZ507211A patent/NZ507211A/en not_active IP Right Cessation
- 1999-03-25 AT AT99909332T patent/ATE269075T1/de active
- 1999-03-25 DE DE69918074T patent/DE69918074T2/de not_active Expired - Lifetime
- 1999-03-25 HU HU0101237A patent/HU230889B1/hu unknown
- 1999-03-25 TR TR2000/02771T patent/TR200002771T2/xx unknown
- 1999-03-25 DK DK10152774.5T patent/DK2198858T3/da active
- 1999-03-25 CZ CZ20003549A patent/CZ300548B6/cs not_active IP Right Cessation
- 1999-03-25 TW TW092115044A patent/TWI235068B/zh not_active IP Right Cessation
- 1999-03-25 KR KR10-2003-7016882A patent/KR100498765B1/ko not_active IP Right Cessation
- 1999-03-25 RU RU2000126836A patent/RU2214244C9/ru active Protection Beyond IP Right Term
- 1999-03-25 JP JP54564199A patent/JP3714970B2/ja not_active Expired - Lifetime
- 1999-03-25 EP EP04002277A patent/EP1421939B9/en not_active Revoked
- 1999-03-25 IL IL13846699A patent/IL138466A/xx not_active IP Right Cessation
- 1999-03-25 BR BRPI9909201A patent/BRPI9909201B8/pt not_active IP Right Cessation
- 1999-03-25 KR KR10-2000-7010438A patent/KR100440553B1/ko active IP Right Grant
- 1999-03-25 AU AU28563/99A patent/AU749623B2/en not_active Expired
- 1999-03-25 ES ES04002277T patent/ES2343248T3/es not_active Expired - Lifetime
- 1999-03-25 DE DE69942286T patent/DE69942286D1/de not_active Expired - Lifetime
- 1999-03-25 SK SK1439-2000A patent/SK286887B6/sk not_active IP Right Cessation
- 1999-03-25 US US09/403,787 patent/US6440458B1/en not_active Expired - Lifetime
- 1999-03-25 CA CA2322516A patent/CA2322516C/en not_active Expired - Lifetime
- 1999-03-25 AT AT04002277T patent/ATE464900T1/de active
- 1999-03-25 TW TW088104712A patent/TW570814B/zh not_active IP Right Cessation
- 1999-03-25 DK DK04002277.4T patent/DK1421939T5/da active
- 1999-03-25 AT AT10152774T patent/ATE514419T1/de active
- 1999-03-25 EP EP99909332A patent/EP1064942B9/en not_active Expired - Lifetime
- 1999-03-26 AR ARP990101353A patent/AR023299A1/es active IP Right Grant
-
2000
- 2000-09-18 ZA ZA200004963A patent/ZA200004963B/en unknown
- 2000-09-25 NO NO20004773A patent/NO330578B1/no not_active IP Right Cessation
- 2000-10-20 HR HR20000707A patent/HRP20000707B1/xx not_active IP Right Cessation
-
2001
- 2001-10-17 US US09/978,025 patent/US6576259B2/en not_active Expired - Lifetime
- 2001-12-14 HK HK01108795A patent/HK1038185A1/xx not_active IP Right Cessation
-
2003
- 2003-04-14 US US10/412,281 patent/US6884433B2/en not_active Expired - Lifetime
-
2004
- 2004-08-18 JP JP2004237947A patent/JP4622382B2/ja not_active Expired - Lifetime
- 2004-08-18 JP JP2004237946A patent/JP3992031B2/ja not_active Expired - Lifetime
-
2005
- 2005-02-17 US US11/059,439 patent/US20050169993A1/en not_active Abandoned
-
2008
- 2008-07-17 JP JP2008186587A patent/JP4992845B2/ja not_active Expired - Lifetime
- 2008-11-05 US US12/265,108 patent/US8551522B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR023299A1 (es) | UNA FORMULACION DE LIBERACION PROLONGADA DE UN COMPUESTO MACRoLIDO | |
DE69701532D1 (de) | Orale zusammensetzung gegen zahnbelag | |
NO20011471D0 (no) | Nye orale vedvarende frigivelsesformuleringer | |
PL360092A1 (en) | Structures and compositions increasing the stability of peroxide actives | |
GB2354596B (en) | Photoresist composition containing photo base generator with photo acid generator | |
DE60042904D1 (de) | Orale Dosiszusammensetzung mit verlängerter Freigabe | |
DE69738300D1 (de) | Pharmazeutische zusammensetzungen mit verzoegerter freisetzung, die wasserunloesliche komplexverbindungen enthalten | |
AR022008A1 (es) | Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento | |
ES2195181T3 (es) | Portaobjetos. | |
DE69925133D1 (de) | Pyrrolobenzodiazepine | |
ATA106594A (de) | Pharmazeutische orale zusammensetzung enthaltend verbindungen der rapamycinklasse | |
MY122704A (en) | Stable hydrogenated lupulone antibacterial oral compositions | |
AU2603400A (en) | Formulations for treating disease and methods of using same | |
IT1231012B (it) | Composizione farmaceutica per uso orale contenente nac. | |
MXPA02012160A (es) | Composiciones medicinales las cuales contienen derivados de propenona. | |
AR021934A1 (es) | Composicion de administracion oral con liberacion controlada de al menos un analgesico | |
ATE356592T1 (de) | Zahnseidenhalter | |
ES2179533T3 (es) | Formulacion de medicamento con liberacion controlada del principio activo. | |
NZ504418A (en) | Delayed release oral dosage form of carvedilol | |
DE69906982D1 (de) | Ibuprofen und domperidone enthaltende pharmazeutische zusammensetzungen | |
AR044863A1 (es) | Una composicion de confiteria que suministra agentes antiplaca a la cavidad oral | |
AR020205A1 (es) | Formulacion efervescente esterilizante. | |
DE50204203D1 (de) | Orale fludara reinst formulierung mit schneller freisetzung des wirkstoffes | |
AR030641A1 (es) | Composicion base de adhesivo para dentaduras, procedimiento para prepararla y composicion estabilizadora de la dentadura que la comprende | |
ATE295154T1 (de) | Zusammensetzungen mit langsamer freigabe enthaltend lithium-carbonat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |